Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90360 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-01

Study Completion Date

2020-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose:

With the existing biologic anti-inflammatory product patents expiring and the FDA approval of new biosimilar and innovator biologics, patients with rheumatologic (RA), psoriatic (PsO-PsA-AS), and gastrointestinal (GI) conditions will have additional therapeutic options. This observational study will describe the patient characteristics of new users of Tumor Necrosis Factor-α (TNF) antagonists, non-TNF- α antagonists, oral DMARD, and non-biologic agents. It will describe in the treatment cohorts outcomes of serious infections that require hospitalization. The BBCIC will use the findings from this descriptive analysis to design a comparative study evaluating the real-world effectiveness and safety of biosimilar and innovator anti-inflammatory biologics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs

NCT03496831

Rheumatoid Arthritis Spondyloarthritis Psoriatic Arthritis

COMPLETED

Brigham and Women's Rheumatoid Arthritis Sequential Study

NCT01793103

Rheumatoid Arthritis

ACTIVE_NOT_RECRUITING

Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics

NCT01166620

Rheumatoid Arthritis

COMPLETED

Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital

NCT06601595

Inflammatory Bowel Disease (IBD) Spondylarthropathies TNF-alpha Inhibitors

NOT_YET_RECRUITING

Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions

NCT00001291

Arthritis, Psoriatic Autoimmune Diseases Joint Diseases +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Additional information:

To most effectively interpret results from this descriptive analysis it is important to consider that this protocol was not designed to support a hypothesis. This information is being provided to the public in the interest of transparency and for demonstrating the BBCIC's Distributed Research Network's (DRN) ability to define exposures, outcomes, covariates and confounders. When published, the report will caution that the protocol does not support any ability to compare safety or effectiveness but instead is to be used only to explore the feasibility of future, more detailed comparative analyses and to better understand the capabilities of the BBCIC project. Further, the report will caution that information from this protocol should not affect use of the medical products described in any way and the fact that the BBCIC is performing this descriptive analysis in no way suggests there is a safety or effectiveness issue with any of the products described.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis Inflammatory Bowel Disease Psoriasis Psoriatic Arthritis Ankylosing Spondylitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rheumatoid arthritis (RA)

With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics

TNF-α antagonists, non-TNFs, DMARD non-biologics

Intervention Type DRUG

Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.

Inflammatory bowel disease (IBD)

With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics

TNF-α antagonists, non-TNFs, DMARD non-biologics

Intervention Type DRUG

Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.

Psoriatic conditions

Patients with a psoriasis, psoriatic arthritis, ankylosing spondylitis with exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics

TNF-α antagonists, non-TNFs, DMARD non-biologics

Intervention Type DRUG

Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TNF-α antagonists, non-TNFs, DMARD non-biologics

Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

18 drug names in TNF, non-TNFs, DMARD non-biologics

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals with baseline period of 365 days with continuous medical and pharmacy coverage preceding the first prescription fill
* new and users of the following exposures

* TNF -α antagonists (including adalimumab, certolizumab, etanercept \[not included for IBD\], golimumab, infliximab, and natalizumab \[IBD only\])
* Non-TNF-alpha antagonist biologics in RA only (abatacept, rituximab, and tocilizumab)
* Non-biologic medications (after any use of methotrexate in the previous year includes RA: hydroxychloroquine, leflunomide, or sulfasalazine; IBD: 6- mercaptopurine or azathioprine; PsO-PsA-AS: methotrexate, leflunomide, or sulfasalazine).

Exclusion Criteria

* During baseline 365 days, any patient with

* Active cancer or a history of non-melanoma cancer\*
* Any immunocompromising conditions (organ transplantation, HIV, and advanced kidney/liver disease)\*
* \*if occur during the follow-up period, patients also will be censored.
* During baseline 183 days, any patient with hospitalization for any infection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No